150 related articles for article (PubMed ID: 24262013)
1. Pemphigus foliaceous-like reaction in a patient with chronic myeloid leukemia treated with the tyrosine kinase inhibitors nilotinib and dasatinib.
Nuno-Gonzalez A; Dehesa L; Ricotti C; Kerdel F
Int J Dermatol; 2014 Apr; 53(4):494-6. PubMed ID: 24262013
[No Abstract] [Full Text] [Related]
2. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
Novitzky-Basso I; Craddock C
Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
[No Abstract] [Full Text] [Related]
3. Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia.
Samimi S; Chu E; Seykora J; Loren A; Vittorio C; Rook A; Rosenbach M; Kim EJ
JAMA Dermatol; 2013 May; 149(5):637-9. PubMed ID: 23677113
[No Abstract] [Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
6. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
7. New and established tyrosine kinase inhibitors for chronic myeloid leukemia.
Thienelt CD; Green K; Bowles DW
Drugs Today (Barc); 2012 Sep; 48(9):601-13. PubMed ID: 23032801
[TBL] [Abstract][Full Text] [Related]
8. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
Eskazan AE; Soysal T; Ongoren S; Gulturk E; Ferhanoglu B; Aydin Y
Haematologica; 2011 Mar; 96(3):e15; author reply e16-7. PubMed ID: 21357709
[No Abstract] [Full Text] [Related]
9. Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors.
Russo Rossi A; Breccia M; Abruzzese E; Castagnetti F; Luciano L; Gozzini A; Annunziata M; Martino B; Stagno F; Cavazzini F; Tiribelli M; Visani G; Pregno P; Musto P; Fava C; Sgherza N; Albano F; Rosti G; Alimena G; Specchia G
Haematologica; 2013 Mar; 98(3):399-403. PubMed ID: 22801965
[TBL] [Abstract][Full Text] [Related]
10. Rash with the multitargeted kinase inhibitors nilotinib and dasatinib: meta-analysis and clinical characterization.
Drucker AM; Wu S; Busam KJ; Berman E; Amitay-Laish I; Lacouture ME
Eur J Haematol; 2013 Feb; 90(2):142-50. PubMed ID: 23240881
[TBL] [Abstract][Full Text] [Related]
11. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Jabbour E; Cortes J; Kantarjian H
Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
[TBL] [Abstract][Full Text] [Related]
13. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia.
Quintás-Cardama A; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma; 2008 Mar; 8 Suppl 3():S82-8. PubMed ID: 19254885
[TBL] [Abstract][Full Text] [Related]
14. Severe dyspnoea in a patient with chronic myelogenous leukaemia on a tyrosine kinase inhibitor.
Ustun C; Randall N; Podgaetz E; Amin K; Dincer HE
Thorax; 2015 Jul; 70(7):701-4. PubMed ID: 25935168
[No Abstract] [Full Text] [Related]
15. The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia.
Chen J; Zheng Z; Shen J; Zhou Y
Leuk Lymphoma; 2010 May; 51(5):941-3. PubMed ID: 20350280
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012.
Romero M; Chávez D; De Los Ríos M; Alvis-Guzmán N
Biomedica; 2014; 34(1):48-59. PubMed ID: 24968906
[TBL] [Abstract][Full Text] [Related]
17. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
Schiffer CA
N Engl J Med; 2007 Jul; 357(3):258-65. PubMed ID: 17634461
[No Abstract] [Full Text] [Related]
18. Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Patel AB; Solomon AR; Mauro MJ; Ehst BD
Dermatology; 2016; 232(1):122-5. PubMed ID: 26352467
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.
Guérin A; Chen L; Wu EQ; Ponce de Leon D; Griffin JD
Curr Med Res Opin; 2012 Jul; 28(7):1155-62. PubMed ID: 22738777
[TBL] [Abstract][Full Text] [Related]
20. Advanced age and prognosis in chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
Stein BL; Smith BD
Leuk Res; 2011 Sep; 35(9):1161-3. PubMed ID: 21782241
[No Abstract] [Full Text] [Related]
[Next] [New Search]